Publications
Selected peer-reviewed studies in outbreak genomics and public-health surveillance, with a short explanation of what each contributes and where its conclusions are limited.
I am first author on the RSV outbreak and Coxsackievirus A24 variant papers below, and a co-author on the other studies. For my wider publication record, see Google Scholar and ORCID. Publication years are shown separately from the study periods.
Archives of Virology 171(3):78.
A study of 320 respiratory specimens collected from January 2023 to January 2024, with 183 positive results across the three viruses. The genomic component included five RSV-B genomes. Its findings describe a sampled clinical population, not population-wide infection rates.
Infection, Genetics and Evolution 134:105815.
Among 388 PCR-positive samples, DENV-2 predominated. The study reported 33 genomes and added evidence on the geographic distribution of circulating lineages. Referred samples do not provide an unbiased estimate of national serotype prevalence.
Journal of Virological Methods 338:115213.
An investigation of 15 conjunctivitis patients during September 2023 identified Coxsackievirus A24 variant in three of the ten samples examined by metagenomic sequencing. The small outbreak series supports pathogen identification but cannot establish the cause of every case in the wider outbreak.
Journal of Medical Virology 96(6):e29727.
DENV-1 predominated among the 98 PCR-positive cases referred between July and October 2023. Eighteen samples were sequenced. Comparing this series with other years requires attention to differences in referral and geographic sampling.
Archives of Virology 169(5):106.
Five of ten RSV-positive samples from December 2022 to January 2023 were sequenced, documenting both RSV-A and RSV-B. This small genomic series describes diversity in the available samples rather than the full outbreak.
Vaccines 11(1):163.
The main August–October 2022 series included 343 NS1-positive samples, of which 293 were successfully serotyped. Ten genomes were reported, including samples collected earlier in April. The different sampling windows matter when interpreting the genomic and serotype results together.